Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration
Joint Authors
Oshima, Kumi
Mori, Jinichi
Kimura, Satoshi
Ikezoe, Takayuki
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-07-27
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
T-cell prolymphocytic leukemia (T-PLL) is a rare hematologic cancer with a dismal prognosis.
Although a small number of patients have central nervous system (CNS) involvement, a standard treatment approach for these patients has not been established.
Herein, we present a case of T-PLL with CNS involvement that was treated with a higher dose of intrathecal alemtuzumab than that previously reported.
A 66-year-old man who had T-PLL with CNS involvement was admitted to our hospital.
Intravenously administered alemtuzumab, a monoclonal antibody against the CD52 antigen, successfully reduced leukemia cells in peripheral blood; however, intrathecal treatment with methotrexate, cytarabine, and prednisone had a limited effect on the CNS involvement.
Therefore, we intrathecally injected alemtuzumab as an experimental treatment.
Although we escalated the dose of intrathecal alemtuzumab up to 5 mg, no adverse reaction was noted; however, this treatment did not completely clear the leukemia cells from the patient’s cerebrospinal fluid (CSF).
We performed whole brain and whole spinal irradiation therapies and subsequently performed allogeneic transplantation from a human leukocyte antigen-matched sibling donor with a conditioning regimen containing total body irradiation.
At 21 days after transplantation, leukemia cells remained in his CSF.
Although intrathecal alemtuzumab did not eliminate the CNS-invading leukemia cells, it was well-tolerated in our case.
Further accumulation of similar cases is needed to determine the benefits and safety of intrathecal alemtuzumab administration.
American Psychological Association (APA)
Mori, Jinichi& Oshima, Kumi& Kimura, Satoshi& Ikezoe, Takayuki. 2020. Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. Case Reports in Hematology،Vol. 2020, no. 2020, pp.1-4.
https://search.emarefa.net/detail/BIM-1147792
Modern Language Association (MLA)
Mori, Jinichi…[et al.]. Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. Case Reports in Hematology No. 2020 (2020), pp.1-4.
https://search.emarefa.net/detail/BIM-1147792
American Medical Association (AMA)
Mori, Jinichi& Oshima, Kumi& Kimura, Satoshi& Ikezoe, Takayuki. Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. Case Reports in Hematology. 2020. Vol. 2020, no. 2020, pp.1-4.
https://search.emarefa.net/detail/BIM-1147792
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1147792